GERON BEGINS TRIAL FOR GRN163L

A A

Geron has initiated clinical testing of its lead anticancer compound, GRN163L, in patients with solid tumor malignancies at The University of Chicago Cancer Research Center.

This Phase I, dose-escalation trial is primarily designed to demonstrate the safety and tolerability of GRN163L administered intravenously (IV) on a weekly basis in patients with refractory or relapsed solid tumor malignancies. This study will also evaluate the tolerability of IV infusions of GRN163L at various rates of administration, and enable an assessment of the pharmacokinetic profile of GRN163L at escalating doses and at decreasing infusion durations. A secondary endpoint of the trial is the preliminary evaluation of anti-tumor activity of GRN163L in this patient population.